Life Sciences Commercial Software
The buyer population — Pharmaceutical and medicine manufacturing
Base industry report for 3254 →- Establishments · CanadaA
- 428
- Under 10 employeesA
- 46%
- Establishments · USA
- 2,882
- Employment · USA
- 314,242
- Payroll · USA
- $33.4B
Of 428 Canadian establishments with employees, 46% have fewer than ten — an industry where large establishments carry real weight. Each of those is one potential account, before any filter for size or fit.
Entry signal — what decides who wins here
Structure decidesThe binding constraint is not executional. Being better than the incumbent does not, by itself, get you in — this one is cleared with capital, an asset, or a permission.
Raise or borrow the entry ticket, or buy an operator who has already paid it. The barrier is money rather than permission, so it yields to a balance sheet — and an acquisition is usually cheaper than a start.
Measured, not forecast: the share of US establishments opening in one year that were still active later. It counts good operators and bad ones together, which is exactly why it is the honest answer to “what are the odds”. It is for the whole sector rather than this market, and the ten-year figure comes from an older cohort because no younger one has reached ten years.
This is not a probability of success, and it is not a verdict on you. No survival probability is published per market, and inventing one would be worse than saying so. What the bar reads is how much of the outcome sits inside an operator's control: green means the hurdles are ones a better operator clears, red means the binding constraint is capital, an asset or a permission rather than execution. Someone arriving with an advantage this screen did not assume can win a market shown in red.
Companies named in this market · 8
The binding constraint — entry cost
Veeva is the proof case every vertical SaaS pitch cites, and it now occupies its category completely. Validated-system requirements (GxP, 21 CFR Part 11) impose a compliance floor measured in years, not months.
Sectors joined: Biotech · Biotech/Oncology · Pharmaceutical Data · Pharmaceutical · Therapeutics · Oncology
[UNVERIFIED] Sector-to-NAICS mapping is analyst judgment — see data/angel-sector-map.json. Counts are a per-record cross-reference and are not additive across records.
The incumbent
Who owns this market and who is coming for it. Fields a screen never reached say so rather than guessing.
Financials & market size — sourced
Figures that came from a filing, a results release or reputable reporting, each carrying its evidence tier.
Market size, derived
Built from the competitor set upward rather than quoted from a forecast. Published TAMs in these categories are frequently reverse-engineered from each other, so any published figure is checked against the vendor arithmetic rather than trusted on its own.
Disclosed revenue from 1 of 5 named vendors. The market is at least this large.
No vendor has both a disclosed revenue and a published share.
Only a revenue floor is known — the true market is larger by whatever the undisclosed vendors earn.
Competitor set · 5 named · 1 disclose revenue
| Name | Revenue | Share | Note |
|---|---|---|---|
| Veeva SystemsNYSE: VEEVA | $3.2B | — | FY2026, FYE 31 Jan 2026, +16% |
| IQVIANYSE: IQVC | not disclosed | — | Technology & Analytics segment not isolated here |
| CertaraNASDAQ: CERTC | not disclosed | — | Listed (NASDAQ: CERT) but the regulatory and quality line is not broken out; not researched for this record |
| Medidata (Dassault)C | not disclosed | — | Not separately disclosed |
| Salesforce Life Sciences CloudC | not disclosed | — | Competes directly since Veeva's move off the Salesforce platform |
Startups & challengers
Newer and smaller vendors going at the incumbent — funded challengers first. Named, not researched to the depth of the field above; a company with a page here links to it.
| Company | Stage | What it does | Raised |
|---|---|---|---|
| AcuityMD | Funded challenger | Commercial intelligence for medtech sales teams: which surgeons and sites to target | — |
| Definitive Healthcare | Funded challenger | Healthcare provider data and commercial intelligence for life-science and health sellers | — |
| Komodo Health | Funded challenger | Healthcare claims data and analytics for life sciences commercial teams. | — |
| Veeva | Funded challenger | Cloud CRM, data and clinical software for pharma and biotech. | — |
Evidence
Evidence. Incumbent financials and market-share figures on this record ARE sourced (tier A/B, see the financials block). The cut factor and reasoning remain analyst judgment and were not tested against customers.
Where the industry talks
The associations, forums and events where people in this trade actually talk shop — where to listen before entering, and where the first customers are found. Each link was opened on the date shown.
Member companies ('40+' per homepage); the research-based pharmaceutical companies whose Canadian commercial and medical teams run Veeva-class systems.
Professional body for regulatory-affairs staff at Canadian pharma and device companies, the people who own validated-system and submission processes. No member count on site.
US trade association of research-based biopharmaceutical companies; policy advocacy body. No member count on homepage.
Global association for clinical, regulatory and drug-development professionals; its DIA Global Annual Meeting is where clinical and regulatory software vendors exhibit. No member count on homepage.
Members ('25,000+ in over 120 countries' per homepage); GAMP and computerised-system validation guidance comes from here. Has a Canada affiliate; 2026 Annual Meeting 18-21 Oct, National Harbor MD.
Magazine for marketing decision makers in pharma, biotech and medical devices; covers CRM, omnichannel and commercial-software vendors.
Haymarket trade title for pharma commercial and medical marketing teams; news, agency rankings and awards.
Fierce Pharma (fiercepharma.com), Life Sciences Ontario and BIOTECanada are live and adjacent but broader than the commercial-software audience. r/pharmaindustry could not be verified.